Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

[Correlation between tumor cell proliferation and prognosis of primary cutaneous malignant melanoma in 127 patients].

Wang Y, Xue WC, Si L, Cui CL, Lu AP, Cao DF, Guo J, Li ZW.

Zhonghua Bing Li Xue Za Zhi. 2013 Mar;42(3):178-81. doi: 10.3760/cma.j.issn.0529-5807.2013.03.008. Chinese.

PMID:
23769437
2.
3.

Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.

Ladstein RG, Bachmann IM, Straume O, Akslen LA.

BMC Cancer. 2010 Apr 14;10:140. doi: 10.1186/1471-2407-10-140.

4.
5.

Prognostic value of Ki-67 expression in localized cutaneous malignant melanoma.

Henrique R, Azevedo R, Bento MJ, Domingues JC, Silva C, Jerónimo C.

J Am Acad Dermatol. 2000 Dec;43(6):991-1000.

PMID:
11100014
6.
7.

Clinicopathological features and pituitary homeobox 1 gene expression in the progression and prognosis of cutaneous malignant melanoma.

Barut F, Udul P, Kokturk F, Kandemir NO, Keser SH, Ozdamar SO.

Kaohsiung J Med Sci. 2016 Oct;32(10):494-500. doi: 10.1016/j.kjms.2016.08.001. Epub 2016 Aug 27.

8.

Immunodetection of phosphohistone H3 as a surrogate of mitotic figure count and clinical outcome in cutaneous melanoma.

Tetzlaff MT, Curry JL, Ivan D, Wang WL, Torres-Cabala CA, Bassett RL, Valencia KM, McLemore MS, Ross MI, Prieto VG.

Mod Pathol. 2013 Sep;26(9):1153-60. doi: 10.1038/modpathol.2013.59. Epub 2013 Apr 5.

9.

Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma.

Nielsen PS, Riber-Hansen R, Jensen TO, Schmidt H, Steiniche T.

Mod Pathol. 2013 Mar;26(3):404-13. doi: 10.1038/modpathol.2012.188. Epub 2012 Nov 23.

10.

How staging of thin melanoma is changed after the introduction of TNM 7th edition: a population-based analysis.

Caldarella A, Fancelli L, Manneschi G, Chiarugi A, Nardini P, Crocetti E.

J Cancer Res Clin Oncol. 2016 Jan;142(1):73-6. doi: 10.1007/s00432-015-2007-1. Epub 2015 Jun 26.

PMID:
26113451
11.

Mitotic rate and S-phase fraction as prognostic factors in stage I cutaneous malignant melanoma.

Karjalainen JM, Eskelinen MJ, Nordling S, Lipponen PK, Alhava EM, Kosma VM.

Br J Cancer. 1998 Jun;77(11):1917-25.

12.
13.

Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohistochemical study.

Niezabitowski A, Czajecki K, Ryś J, Kruczak A, Gruchała A, Wasilewska A, Lackowska B, Sokołowski A, Szklarski W.

J Surg Oncol. 1999 Mar;70(3):150-60.

PMID:
10102344
14.

Melastatin expression and prognosis in cutaneous malignant melanoma.

Duncan LM, Deeds J, Cronin FE, Donovan M, Sober AJ, Kauffman M, McCarthy JJ.

J Clin Oncol. 2001 Jan 15;19(2):568-76.

PMID:
11208852
15.

Mitotic rate in cutaneous melanomas ≤1 mm in thickness: a prospective study.

Litzner BR, Etufugh CN, Stepenaskie S, Hynan LS, Cockerell CJ.

Am J Dermatopathol. 2012 Dec;34(8):827-32. doi: 10.1097/DAD.0b013e3182604d96.

PMID:
22878366
16.

Identification of higher risk thin melanomas should be based on Breslow depth not Clark level IV.

Owen SA, Sanders LL, Edwards LJ, Seigler HF, Tyler DS, Grichnik JM.

Cancer. 2001 Mar 1;91(5):983-91.

PMID:
11251950
17.

[Prognostic factors of localized malignant melanoma: study of 639 patients].

Nagore Enguídanos E, Oliver Martínez V, Botella Estrada R, Insa Mollá A, Fortea Baixauli JM.

Med Clin (Barc). 2005 Mar 19;124(10):361-7. Spanish.

PMID:
15766505
18.

Primary cutaneous melanoma. Optimized cutoff points of tumor thickness and importance of Clark's level for prognostic classification.

Büttner P, Garbe C, Bertz J, Burg G, d'Hoedt B, Drepper H, Guggenmoos-Holzmann I, Lechner W, Lippold A, Orfanos CE, et al.

Cancer. 1995 May 15;75(10):2499-2506.

19.

Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate.

Svobodová S, Browning J, MacGregor D, Pollara G, Scolyer RA, Murali R, Thompson JF, Deb S, Azad A, Davis ID, Cebon JS.

Eur J Cancer. 2011 Feb;47(3):460-9. doi: 10.1016/j.ejca.2010.09.042. Epub 2010 Nov 4.

PMID:
21115342
20.

Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma.

Harcharik S, Bernardo S, Moskalenko M, Pan M, Sivendran M, Bell H, Hall LD, Castillo-Martín M, Fox K, Cordon-Cardo C, Chang R, Sivendran S, Phelps RG, Saenger Y.

J Am Acad Dermatol. 2014 Jun;70(6):1036-44. doi: 10.1016/j.jaad.2014.01.914. Epub 2014 Mar 31.

PMID:
24698703

Supplemental Content

Support Center